Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel H Russell

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Blood|July 11, 2013
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survivalAlan K Burnett, Nigel H Russell, Ann E Hunter, et al.
British Journal of Haematology|December 19, 2018
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphomaSimon Rule, Gordon Cook, Nigel H Russell, et al.
Haematologica|August 20, 2016
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantationPaul Ferguson, Robert K Hills, Angela Grech, et al.
British Journal of Haematology|April 17, 2015
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blastsNaeem Khan, Sylvie D Freeman, Paul Virgo, et al.
British Journal of Haematology|November 25, 2003
The outcome of unrelated donor stem cell transplantation for patients with multiple myelomaBronwen E Shaw, Karl Peggs, Jennifer M Bird, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Haematologica|July 7, 2018
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trialAlan K Burnett, Emma Das Gupta, Steve Knapper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemiaAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
British Journal of Haematology|May 22, 2008
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasiaEleni Tholouli, Effie Liakopoulou, Hayley M Greenfield, et al.
British Journal of Haematology|March 6, 2008
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphomaWendy Ingram, Stephen Devereux, Emma P Das-Gupta, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Blood|July 11, 2013
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survivalAlan K Burnett, Nigel H Russell, Ann E Hunter, et al.
British Journal of Haematology|December 19, 2018
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphomaSimon Rule, Gordon Cook, Nigel H Russell, et al.
Haematologica|August 20, 2016
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantationPaul Ferguson, Robert K Hills, Angela Grech, et al.
British Journal of Haematology|April 17, 2015
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 low blastsNaeem Khan, Sylvie D Freeman, Paul Virgo, et al.
British Journal of Haematology|November 25, 2003
The outcome of unrelated donor stem cell transplantation for patients with multiple myelomaBronwen E Shaw, Karl Peggs, Jennifer M Bird, et al.
British Journal of Haematology|October 3, 2002
Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimensJane E Parker, Tariq Shafi, Antonio Pagliuca, et al.
Haematologica|July 7, 2018
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trialAlan K Burnett, Emma Das Gupta, Steve Knapper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemiaAlan K Burnett, Nigel H Russell, Robert K Hills, et al.
British Journal of Haematology|May 22, 2008
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasiaEleni Tholouli, Effie Liakopoulou, Hayley M Greenfield, et al.
British Journal of Haematology|March 6, 2008
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphomaWendy Ingram, Stephen Devereux, Emma P Das-Gupta, et al.
Pageof 12